Aurinia stock falls on Teva patent settlement for voclosporin
Aurinia Pharmaceuticals (AUPH) shares fell 2% after announcing a patent settlement with Teva (TEVA) for generic voclosporin, allowing Teva to launch its version no earlier than 2036. The agreement validates Aurinia's patents and resolves litigation. Voclosporin is marketed as LUPKYNIS for lupus nephritis. Aurinia continues patent actions against other companies.
How this was made
The 30-second read
Why it matters
The settlement resolves specific Teva voclosporin ANDA litigation by setting a delayed launch date and affirming Aurinia’s US patents as enforceable/valid, subject to FDA approval and defined contingencies.
Market read
A patent settlement can reset perceived generic-entry risk and exclusivity duration, driving immediate repricing in branded specialty pharma names.
What to watch
Aurinia’s other ongoing infringement actions against multiple companies could dominate longer-term risk, and the settlement’s FDA-approval contingency may add uncertainty to the actual launch date.
Background
Voclosporin is marketed as LUPKYNIS, first FDA-approved oral therapy for adult active lupus nephritis in Jan 2021.
Ticker impact
Aurinia shares fell after-hours as it announced a Teva patent settlement that delays Teva’s generic voclosporin launch until Dec. 7, 2036.
Likely supports downside in AUPH versus a no-settlement scenario, but the immediate tape reaction is negative given the market focus on generic risk.
The article states enforceability/validity of Aurinia patents through Dec. 2037 and a generic launch cap to Dec. 2036, yet the stock still dropped 2% after-hours, implying traders weigh litigation/generic overhang more than the settlement’s exclusivity protections.
Market effects
Highlights ongoing patent-portfolio leverage in branded specialty pharma and the importance of ANDA litigation outcomes for generic launch timing.
Primarily US-focused due to FDA approval contingency and US patent enforceability language.
Limited, as the settlement terms described are US-specific and tied to US FDA approval.
Counterpoint
Traders may be over-discounting the settlement’s exclusivity value because the generic launch is pushed out to 2036, with Aurinia’s patents explicitly deemed enforceable and infringed.
Key entities
- companyAurinia Pharmaceuticals Inc.
Subject of the article; announced a patent settlement with Teva affecting generic voclosporin launch timing in the US.
- companyTeva Pharmaceuticals Inc.
Counterparty in the settlement that can pursue a generic voclosporin launch no earlier than Dec. 7, 2036, subject to contingencies and FDA approval.
- companyDifGen Pharmaceuticals LLC
Named as having ongoing related patent infringement actions with Aurinia.
- companyDr. Reddy’s Laboratories Inc.
Named as having ongoing related patent infringement actions with Aurinia.
- companyHikma Pharmaceuticals USA Inc.
Named as having ongoing related patent infringement actions with Aurinia.
